Consistent with the findings in vitro, SHP099 at its maximum tolerated dose of 100 mg per kilogram bodyweight (mpk) daily (QD) had no anti-tumor effect while the FGFR4 inhibitor FGF401 [25] dosed at 30 mpk twice every day (BID) effectively suppressed tumor growth (Figure 1D). This evidence concerns the gene FGFR4 and neoplasm.